Miraculins Inc.

Miraculins Inc.

October 11, 2006 09:03 ET

Miraculins Announces Successful ELISA Test Development

WINNIPEG, MANITOBA--(CCNMatthews - Oct. 11, 2006) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it has successfully detected the primary protein biomarker from its prostate cancer diagnostic, using an ELISA based immunoassay.

"This is a very important step for the Company", said Dr. Jim Charlton, President of Miraculins. "While we use mass spectrometry as our main tool of discovery, it is not a readily available or accepted diagnostic tool in most clinical laboratories. The development of immunoassays for our biomarkers is a critical step in preparation for marketing the final diagnostic test".

The colorimetric based ELISA test that was utilized by the Miraculins' research team was also able to produce results in a sample subset consistent with the diagnostic results observed when using mass spectrometry for detection. The successful measurement of the biomarker using an immunoassay marks the first time that Miraculins has used an alternative diagnostic method in the verification of its research.

"Miraculins now plans to develop a more sensitive and complex ELISA test under contract with an outside manufacturer. This will move the Company that much closer to having a developed test ready for regulatory approval", added Charlton.

About Prostate Cancer

Prostate cancer is responsible for greater than 240,000 new cancer diagnoses in North America each year. The current screening standard for prostate cancer, PSA, is ineffective at reliably distinguishing between non-life threatening prostate conditions and critical prostate cancer. There are greater than 25 million PSA tests performed annually in the United States alone, resulting in one million prostate biopsy procedures. 75% of these biopsies produce negative test results which would be avoidable if an improved diagnostic technique were available.

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's BEST™ Platform utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information